Ophthalmology. Retina最新文献

{"title":"Highly Myopic Macular Hole Surgery by the Internal Limiting Membrane Flap with No Gas Tamponade Technique: A Prospective Interventional Case Series.","authors":"Simon K H Szeto, Amy H Y Yu, Vivian W K Hui, Julia T W Lam, Ken K Tsang, Timothy P H Lin, Christopher M K Pang, Ziqi Tang, Timothy Y Y Lai, Shaheeda Mohamed, Chi Wai Tsang","doi":"10.1016/j.oret.2026.04.023","DOIUrl":"https://doi.org/10.1016/j.oret.2026.04.023","url":null,"abstract":"<p><strong>Purpose: </strong>To report the surgical outcomes of the internal limiting membrane (ILM) flap with no gas tamponade technique in managing high myopia associated macular hole (MH).</p><p><strong>Design: </strong>Prospective interventional case series.</p><p><strong>Participants: </strong>Patients with high myopia associated full thickness MH.</p><p><strong>Methods: </strong>Consecutive patients with high myopia associated MH were prospectively recruited. High myopia was defined as refraction of spherical equivalence (SE) of ≤ -6.0D (in phakic eyes) or axial length (AL) ≥26mm. The ILM flap without gas tamponade technique was used for MH repair, conversion to conventional surgery with gas tamponade is a contingency surgical plan when necessary.</p><p><strong>Main outcomes measures: </strong>Primary outcome was the MH closure rate at week 12. Key secondary outcomes included post-operative best corrected visual acuity (BCVA) and time to MH closure.</p><p><strong>Results: </strong>Twenty eyes from 20 patients were included. The mean age was 67.2 years, and median duration of symptoms was 9.5 months. The mean ± standard deviation (SD) baseline logarithm of the minimum angle of resolution (logMAR) BCVA was 0.77 ± 0.39, mean axial length (AL) was 28.9mm ± 2.20 and the mean minimum linear diameter (MLD) was 424.0μm ± 197.7. All participants underwent the planned study intervention and completed week 12 visit for the assessment of primary outcome. MH closure was achieved in 20 (100%) eyes at week 12 and the median time to MH closure was 1 week (range, 0-12 weeks). The post-operative mean logMAR BCVA was 0.75 ± 0.29 (p=0.832), 0.50 ± 0.25 (p=0.013), 0.36 ± 0.21 (p<0.001), 0.30 ± 0.21 (p<0.001) and 0.25 ± 0.23 (p<0.001) at post-operative day 1, week 1, 4, 12 and 24, respectively. The number of eyes with BCVA ≥ 20/50 increased from 6 (30%) on day 1 to 12 (60%), 17 (85%), 18 (90%) and 18 (94.7%) at week 1, 4, 12 and 24, respectively.</p><p><strong>Conclusions: </strong>The ILM flap with no gas tamponade technique is effective in repairing high myopia associated MH, achieving a high closure rate and quick post-operative visual recovery. Results from this study support the need for a collaborative multi-center randomized controlled trial.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Time From Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase 3 Trials.","authors":"Sumit Sharma, Dilsher S Dhoot, Dilraj S Grewal, Eric Jung, Fabiana Q Silva, Weiming Du, Hadi Moini, David S Boyer","doi":"10.1016/j.oret.2026.04.027","DOIUrl":"https://doi.org/10.1016/j.oret.2026.04.027","url":null,"abstract":"<p><strong>Objective: </strong>To examine impacts of time since diagnosis of macular edema following central or branch retinal vein occlusion (MEfCRVO or MEfBRVO) to first intravitreal aflibercept 2 mg injection (IAI) and baseline best-corrected visual acuity (BCVA) on visual and anatomic outcomes, to inform treatment decisions and management of physician and patient expectations.</p><p><strong>Design: </strong>Post hoc analysis of 3 clinical trials.</p><p><strong>Participants: </strong>Patients with MEfCRVO from COPERNICUS and GALILEO treated with IAI every 4 weeks then as needed from Week 24 to 100 (COPERNICUS) or 76 (GALILEO) and patients with MEfBRVO from VIBRANT treated with IAI 2 mg every 4 weeks then every 8 weeks from Week 24 to 52.</p><p><strong>Methods: </strong>Patients were grouped by time from initial MEfCRVO/MEfBRVO diagnosis to first IAI, < 1, 1-3, or > 3 months (COPERNICUS/GALILEO), and < 1 or ≥ 1 month (VIBRANT).</p><p><strong>Main outcome measures: </strong>Impact of baseline BCVA was evaluated by tertiles: T1, ≤ 44; T2, > 44-≤ 58; T3, > 58 letters (COPERNICUS), T1, ≤ 47; T2, > 47-≤ 65; T3, > 65 letters (GALILEO), and T1, ≤ 55; T2, > 55-≤ 64; T3, > 64 letters (VIBRANT).</p><p><strong>Results: </strong>In COPERNICUS, 113 patients initiated IAI at < 1 (n = 44; 38.9%), 1-3 (n = 33; 29.2%), or > 3 months (n = 36; 31.9%) post-diagnosis; mean BCVA gains from baseline at Week 24 were 19.8, 15.6, and 11.9 letters, respectively (mean [95% CI] difference between < 1-month and > 3-month groups: +7.9 [1.7, 14.1]; P = 0.01). Central retinal thickness (CRT) decrease from baseline at Week 24 across time-since-diagnosis subgroups was -466.6, -456.4, and -479.2 μm, respectively. Least squares mean BCVA gains from baseline at Week 100 were greater for baseline BCVA T1 versus T2/T3 (16.5 vs 8.9/5.9 letters) but final BCVA was lower (49.8 vs 60.9/71.2 letters, respectively). CRT at Week 100 was similar across T1-T3 (243.8-291.5 μm, respectively). Outcomes were similar in GALILEO and VIBRANT.</p><p><strong>Conclusion: </strong>In MEfCRVO/MEfBRVO, longer time to IAI treatment initiation was followed by less visual improvement. Poor baseline BCVA was associated with greater visual improvement but worse final BCVA.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Uveitic Macular Edema in Non-Infectious Uveitis: Structural and Visual Outcomes and Predictors of Visual Prognosis.","authors":"Alessandro Feo, Shani Pillar, Paolo Forte, Alberto Quarta, Justin S Yun, Anamika Patel, Marko M Popovic, Kelly K Tran, Edmund Tsui","doi":"10.1016/j.oret.2026.04.021","DOIUrl":"https://doi.org/10.1016/j.oret.2026.04.021","url":null,"abstract":"<p><strong>Purpose: </strong>To characterize the clinical features, multimodal imaging findings, and long-term visual and structural outcomes of pediatric uveitic macular edema (UME), and to identify longitudinal predictors of visual prognosis.</p><p><strong>Design: </strong>Retrospective observational cohort study.</p><p><strong>Participants: </strong>Thirty-one eyes of 20 pediatric patients with noninfectious uveitis complicated by UME treated at a tertiary referral center.</p><p><strong>Methods: </strong>Medical records of children diagnosed with UME were retrospectively reviewed. Baseline was defined as the first visit demonstrating intraretinal cysts on spectral-domain optical coherence tomography (OCT). Clinical, imaging, and treatment data were collected at baseline, visits closest to 3, 6, and 12 months, and last available follow-up. OCT parameters included central macular thickness (CMT), subfoveal choroidal thickness (SFCT), intraretinal fluid (IRF), subretinal fluid (SRF), intraretinal hyperreflective foci (IHRF), disorganization of retinal inner layers (DRIL), and ellipsoid zone/external limiting membrane (EZ/ELM) disruption. Longitudinal outcomes were analyzed using linear mixed-effects models accounting for inter-eye correlation.</p><p><strong>Main outcome measures: </strong>Best-corrected visual acuity (BCVA), OCT structural changes, inflammatory control, treatment patterns, and predictors of BCVA at 12 months.</p><p><strong>Results: </strong>Median age at baseline was 13 years (IQR, 9-14) with a median follow-up of 3.2 years (IQR, 1.5-4.5). Median BCVA improved from 0.4 logMAR (20/50; IQR 0.18-0.88) at baseline to 0.18 logMAR (∼20/30; IQR, 0-0.51) at final follow-up (p=0.002). Median CMT significantly decreased from 422 μm (IQR, 350-532) at baseline to 292 μm (IQR, 264-328) at last follow-up (p<0.001). The proportion of eyes with IRF declined from 100% (31/31) at baseline to 19.2% (5/31) at final follow-up, and SRF resolved in all eyes from 6 months onward (p<0.001). Inflammatory activity also decreased significantly over time. Use of immunomodulatory therapy increased from 30% at baseline to 90% at final follow-up (p<0.001), whereas systemic corticosteroid use progressively declined. In multivariable analysis, worse BCVA (p<0.001) and EZ/ELM disruption (p=0.006) during early follow-up independently predicted worse BCVA at 12 months.</p><p><strong>Conclusions: </strong>Pediatric UME demonstrates substantial anatomical improvement and stabilization of visual function under contemporary immunomodulatory strategies. Early BCVA and photoreceptor layer integrity (EZ/ELM) were associated with visual outcomes and may help identify children at risk for poorer prognosis requiring earlier therapeutic escalation.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Based Prognostic Models for Postoperative Outcomes in Vitreoretinal Surgery: A Systematic Review and Meta-Analysis.","authors":"Abdullah Al-Ani, Liam Connors, David Mikhail, Mayar Alkhawaja, Lucy Yang, Athithan Ambikkumar, Karim Punja, Fiona Costello, Patrick Gooi, Monique Munro","doi":"10.1016/j.oret.2026.04.022","DOIUrl":"https://doi.org/10.1016/j.oret.2026.04.022","url":null,"abstract":"<p><strong>Topic: </strong>This review evaluated the performance of artificial intelligence (AI) models for predicting outcomes following vitreoretinal surgery compared with conventional statistical approaches.</p><p><strong>Clinical relevance: </strong>The ability of AI to analyze high volume and diverse data may augment preoperative prognostication to better facilitate counselling and surgical planning.</p><p><strong>Methods: </strong>Following registration [NPLASY202380012; doi:10.37766/inplasy2023.8.0012], a search was conducted in MEDLINE, Embase, Cochrane databases, Compendex, IEEE, Web of Science, and Scopus, supplemented by grey literature-primary studies using AI to predict vitreoretinal surgical outcomes were included. Studies involving laser procedures, intraocular lens calculations, or non-predictive models were excluded. Risk of bias was evaluated using the Prediction Model Risk of Bias Assessment Tool (PROBAST), and the overall quality of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation framework.</p><p><strong>Results: </strong>Of 827 abstracts screened, 26 studies (18,724 eyes) met eligibility criteria; 12 studies were eligible for meta-analysis. Males accounted for 52% (n=9,807) of included patients. The most common surgical indication was macular hole (n=10, 40%). Convolutional neural networks (CNNs) were the most investigated deep learning algorithms (n=7, 30%), with best corrected visual acuity being the highest frequency outcome (n=12, 46%). Most studies (n=8, 69%) reported deep learning or machine learning outperformance to conventional statistical approaches. Across pooled outcomes, ground truth was defined as clinician-ascertained presence of post-operative outcome during follow-up in each study. A meta-analysis of 12 studies (n=4,536 participants) revealed a pooled sensitivity of 0.89 (95% CI: 0.83; 0.93; I²=85.7%), reflecting the models' ability to correctly identify eyes that achieved the predicted post-operative outcome, and pooled specificity of 0.87 (95% CI: 0.81; 0.91; I²=93.9%), reflecting the models' ability to correctly identify eyes that did not achieve the predicted outcome. Pooled accuracy was 0.87 (95% CI: 0.83; 0.90; I²=94.3%), and all outcomes were rated as low certainty evidence. Meta-regression identified study location as significant source of heterogeneity; 12 of 26 studies were designated as high risk of bias in at least one PROBAST domain.</p><p><strong>Conclusion: </strong>AI-based models show promise in forecasting vitreoretinal surgical outcomes to support clinical decision-making. Further external validation and clinical implementation studies are needed to confirm generalizability and utility.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OCT Risk Factors for Progression to Late-Stage Age-Related Macular Degeneration in the Amish Eye Study","authors":"Yu-Chien Chung MD, PhD ,&nbsp;Mai Alhelaly MD ,&nbsp;Muneeswar G. Nittala OD, PhM ,&nbsp;Swetha B. Velaga OD, MS ,&nbsp;Ye He MD, PhD ,&nbsp;Jonathan L. Haines PhD ,&nbsp;Margaret A. Pericak-Vance PhD ,&nbsp;Dwight Stambolian MD, PhD ,&nbsp;SriniVas R. Sadda MD","doi":"10.1016/j.oret.2026.01.010","DOIUrl":"10.1016/j.oret.2026.01.010","url":null,"abstract":"<div><h3>Purpose</h3><div>To characterize the prevalence of some critical OCT biomarkers—including cuticular drusen and acquired vitelliform lesions (AVLs)—and to identify their relative risk for progression to late age-related macular degeneration (AMD) over 2 years in subjects with early or intermediate AMD in the Amish Eye Study.</div></div><div><h3>Design</h3><div>Prospective, observational, longitudinal, population-based cohort study.</div></div><div><h3>Participants</h3><div>This study included 276 eyes from 171 subjects with early or intermediate AMD at baseline who completed the 2-year follow-up.</div></div><div><h3>Methods</h3><div>Baseline OCT scans were evaluated for the presence of cuticular drusen, AVLs, subretinal drusenoid deposits (SDDs), high drusen volume (defined as ≥0.2 mm³ within the central 5 mm), intraretinal hyperreflective foci (IHRF), hyporeflective drusen cores (hDCs), thick/thin double-layer sign (DLS), and incomplete retinal pigment epithelium and outer retinal atrophy (iRORA). Subfoveal choroidal thickness (SFCT) was also measured.</div></div><div><h3>Main Outcome Measures</h3><div>Incidence of late AMD (geographic atrophy or macular neovascularization) at 2 years as determined by multimodal imaging (OCT, color fundus photography, and confocal fundus autofluorescence).</div></div><div><h3>Results</h3><div>By 2 years of follow-up, 26 eyes (10.7%) progressed to late AMD. The most prevalent baseline features in this cohort, in descending order, were cuticular drusen (52.3%), IHRF (17.3%), hDC (16.0%), thin DLS (11.9%), SDD (8.2%), iRORA (7.8%), AVL (7.0%), and high drusen volume (2.5%). The mean SFCT was 243.23 ± 75.45 μm. Univariate analysis demonstrated that the presence of thick DLS, iRORA, AVL, SDD, IHRF, hDC, and SFCT was associated with an increased risk of progression. In multivariate regression, only the presence of iRORA (odds ratio [OR], 29.60; 95% confidence interval [CI], 6.86–127.84; <em>P</em> &lt; 0.001) and AVL (OR, 15.90; 95% CI, 3.24–78.00; <em>P</em> &lt; 0.001) remained significant, whereas the presence of IHRF showed borderline significance (OR, 4.71; 95% CI, 1.00–22.16; <em>P</em> = 0.050).</div></div><div><h3>Conclusions</h3><div>In this cohort, the presence of iRORA and AVL was independently associated with progression to late AMD over 2 years. Although cuticular drusen were highly prevalent, their presence<em>,</em> as assessed in this study, was not significantly associated with an increased risk of progression to late AMD.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 499-507"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146041408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Glucagon-Like Peptide-1 Receptor Agonists on Age-Related Macular Degeneration at a Tertiary Ophthalmology Center","authors":"Julia H. Joo MD, MPH ,&nbsp;Alison H. Zhao BA ,&nbsp;Meghana Chalasani MD ,&nbsp;Kevin C. Allan MD, PhD ,&nbsp;Aleksandra V. Rachitskaya MD","doi":"10.1016/j.oret.2025.12.014","DOIUrl":"10.1016/j.oret.2025.12.014","url":null,"abstract":"<div><h3>Objective</h3><div>There is ongoing debate in the literature on the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on age-related macular degeneration (AMD). This study examines the effect of GLP-1RA on the risk of AMD development compared with other glucose-lowering medications at a single ophthalmology center.</div></div><div><h3>Design</h3><div>Retrospective cohort study.</div></div><div><h3>Subjects</h3><div>A total of 30 515 GLP-1RA users, 48 906 sodium–glucose transport protein 2 inhibitor (SGLT-2i) users, 286 066 metformin users, and 164 361 insulin users aged ≥50 years had a 1-year minimum drug duration between 2016 and 2025. After propensity score matching (PSM), each cohort included 7561 patients. Patients with diabetic macular edema, severe or proliferative diabetic retinopathy, and with history of prior retinal surgeries were excluded.</div></div><div><h3>Methods</h3><div>The relative risk (RR) of developing nonexudative AMD was measured at yearly drug duration intervals up to 3 years using logistic regression models controlling for age, sex, race, smoking status, and hemoglobin A1C percentage. Manual review was performed on a random sampling of AMD cases to optimize accuracy. Cox proportional hazards (CPHs) validation analyses in PSM cohorts were performed, matching additionally for body mass index, history of hypertension, chronic kidney disease, and diabetes duration.</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome was the RR of nonexudative AMD up to 3 years on GLP-1RAs compared with alternative antihyperglycemic agents.</div></div><div><h3>Results</h3><div>Glucagon-like peptide-1 receptor agonist was associated with decreased risk of nonexudative AMD compared with metformin and insulin at all 3 years and compared with SGLT-2i only after 3 years of use (3 years: metformin relative risk [RR] = 0.25; 95% confidence interval [CI], 0.14–0.41; insulin RR = 0.28; 95% CI, 0.15–0.46; SGLT-2i RR = 0.42; 95% CI, 0.22–0.74). In PSM cohorts, CPH analyses showed a reduced risk only compared with insulin (hazards ratio = 0.45; 95% CI, 0.27–0.76).</div></div><div><h3>Conclusions</h3><div>Glucagon-like peptide-1 receptor agonist use was associated with a lower risk of nonexudative AMD compared with metformin, insulin, and SGLT-2i in logistic regression models. The risk reduction persisted for insulin in CPH analyses in smaller PSM cohorts.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 480-489"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Barresi et al: Surgical and observational outcomes in optic pit maculopathy: a comparative analysis of pediatric and adult populations(Ophthalmol Retina. 2026;10:445-454)","authors":"Dhananjay Shukla MS, MAMS","doi":"10.1016/j.oret.2026.02.005","DOIUrl":"10.1016/j.oret.2026.02.005","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Page e37"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147290364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-Widefield OCT Angiography Imaging in Pediatric Microphthalmos Using Swept-Source OCT","authors":"Bingfeng Wang MD ,&nbsp;Xiuhua Liu MD ,&nbsp;Lei Gao MD","doi":"10.1016/j.oret.2025.08.007","DOIUrl":"10.1016/j.oret.2025.08.007","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Page e43"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Mottled Fundus Sheen in a Highly Myopic Patient with Oguchi Disease","authors":"Jinlian Zhan MD,&nbsp;Lin Lu MD, PhD,&nbsp;Xiujuan Zhao MD, PhD","doi":"10.1016/j.oret.2025.08.016","DOIUrl":"10.1016/j.oret.2025.08.016","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Page e46"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145150423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Chemotherapy in Retinoblastoma with Postlaminar Optic Nerve Invasion","authors":"Michelle Lin BS ,&nbsp;Sarah B. Pike MD ,&nbsp;Mark W. Reid PhD ,&nbsp;Douglas Chigane MD ,&nbsp;Brianne Brown MPH ,&nbsp;Swathi Kaliki MD ,&nbsp;Jesse L. Berry MD","doi":"10.1016/j.oret.2025.12.018","DOIUrl":"10.1016/j.oret.2025.12.018","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate outcomes of patients with retinoblastoma (RB) who underwent primary enucleation with histopathologic evidence of postlaminar optic nerve invasion (PLONI), comparing those who received adjuvant chemotherapy to those who did not.</div></div><div><h3>Design</h3><div>Multicenter retrospective cohort study.</div></div><div><h3>Participants</h3><div>A total of 292 patients across 9 countries with RB and histopathologic evidence of PLONI after primary enucleation.</div></div><div><h3>Methods</h3><div>Patients who received adjuvant chemotherapy (<em>n</em> = 276) were compared with those who did not (<em>n</em> = 16) using Fisher exact tests, Welch <em>t</em> tests, and proportional hazard models (Cox and competing risks). Subanalyses were performed for PLONI and massive choroidal invasion and isolated PLONI.</div></div><div><h3>Main Outcome Measures</h3><div>Orbital tumor recurrence, metastasis, and death.</div></div><div><h3>Results</h3><div>Patients who did not receive adjuvant chemotherapy had higher rates of orbital tumor recurrence (31% vs 2%, <em>P</em> &lt; 0.001), metastasis (31% vs 6%, <em>P</em> = 0.001), and death (38% vs 9%, <em>P</em> = 0.007). In time-to-event analyses, patients who did not receive adjuvant chemotherapy experienced greater hazard of orbital tumor recurrence (subhazard ratio [SHR] = 19.31, 95% confidence interval [CI]: 5.56–67.05), metastasis (SHR = 5.39, 95% CI: 1.75–16.60), and death (hazard ratio = 4.74, 95% CI: 1.75–12.81). Outcomes were similar among patients with PLONI and massive choroidal invasion. Among patients with isolated PLONI, those who did not receive adjuvant chemotherapy showed significantly greater hazard of metastasis over time than those who received adjuvant chemotherapy (SHR = 40.68, 95% CI: 9.65–171.55, <em>P</em> &lt; 0.001). All patients with metastasis or orbital tumor recurrence eventually died during follow-up (mean duration: 75.3 months).</div></div><div><h3>Conclusions</h3><div>In patients with RB and PLONI with additional high-risk histopathologic features, initiating adjuvant chemotherapy after primary enucleation significantly reduced rates of orbital tumor recurrence, metastasis, and death. Although patients with isolated PLONI experienced fewer events and had a lower metastatic risk compared with those with multiple histopathologic features, adjuvant chemotherapy still reduced metastatic risk over time.</div></div><div><h3><strong>Financial Disclosure(s)</strong></h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"10 5","pages":"Pages 562-572"},"PeriodicalIF":5.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145878097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}